Immupharma PLC - London-based drug discovery and development company - Says its Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, has met the key endpoints requested. The study is part of an international phase 3 trial of the Lupuzor treatment for patients with lupus disease. The dosing of healthy subjects started on February 15 and showed that P140 was safe and well-tolerated across all doses and in all subjects. Notes that the positive data now clears the path for the start of all clinical studies within the P140 platform. Adds that there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy, a rare neurological disorder.
Current stock price: 8.43 pence, up 49% on Wednesday
12-month change: down 12%
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Immupharma (IMM)